| EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy JG Paez, PA Janne, JC Lee, S Tracy, H Greulich, S Gabriel, P Herman, ... Science 304 (5676), 1497-1500, 2004 | 12063 | 2004 |
| Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study Nature medicine 14 (8), 822-827, 2008 | 1132 | 2008 |
| Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non–small cell lung cancer PC Ma, R Jagadeeswaran, S Jagadeesh, MS Tretiakova, V Nallasura, ... Cancer research 65 (4), 1479-1488, 2005 | 684 | 2005 |
| Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia M Bentires-Alj, JG Paez, FS David, H Keilhack, B Halmos, K Naoki, ... Cancer research 64 (24), 8816-8820, 2004 | 623 | 2004 |
| Prognostic and predictive gene signature for adjuvant chemotherapy in resected non–small-cell lung cancer CQ Zhu, K Ding, D Strumpf, BA Weir, M Meyerson, N Pennell, RK Thomas, ... Journal of clinical oncology 28 (29), 4417-4424, 2010 | 507 | 2010 |
| Missense mutations of the BRAF gene in human lung adenocarcinoma K Naoki, TH Chen, WG Richards, DJ Sugarbaker, M Meyerson Cancer research 62 (23), 7001-7003, 2002 | 384 | 2002 |
| Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis X Zhao, BA Weir, T LaFramboise, M Lin, R Beroukhim, L Garraway, ... Cancer research 65 (13), 5561-5570, 2005 | 367 | 2005 |
| Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts DN Hayes, S Monti, G Parmigiani, CB Gilks, K Naoki, A Bhattacharjee, ... Journal of Clinical Oncology 24 (31), 5079-5090, 2006 | 343 | 2006 |
| Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC H Terai, K Soejima, H Yasuda, S Nakayama, J Hamamoto, D Arai, ... Molecular cancer research 11 (7), 759-767, 2013 | 224 | 2013 |
| Hypercapnic acidosis attenuates endotoxin-induced nuclear factor-κB activation K Takeshita, Y Suzuki, K Nishio, O Takeuchi, K Toda, H Kudo, N Miyao, ... American journal of respiratory cell and molecular biology 29 (1), 124-132, 2003 | 208 | 2003 |
| Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays KK Dobbin, DG Beer, M Meyerson, TJ Yeatman, WL Gerald, JW Jacobson, ... Clinical cancer research 11 (2), 565-572, 2005 | 203 | 2005 |
| Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients JP Koivunen, J Kim, J Lee, AM Rogers, JO Park, X Zhao, K Naoki, ... British journal of cancer 99 (2), 245-252, 2008 | 196 | 2008 |
| In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer T Hirano, H Yasuda, T Tani, J Hamamoto, A Oashi, K Ishioka, D Arai, ... Oncotarget 6 (36), 38789, 2015 | 172 | 2015 |
| Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells H Watanabe, K Soejima, H Yasuda, I Kawada, I Nakachi, S Yoda, K Naoki, ... Cancer cell international 8, 1-12, 2008 | 160 | 2008 |
| Amplification of EGFR wild-type alleles in non–small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors S Nukaga, H Yasuda, K Tsuchihara, J Hamamoto, K Masuzawa, I Kawada, ... Cancer research 77 (8), 2078-2089, 2017 | 154 | 2017 |
| Inhibition of c-Jun NH2-terminal kinase activity improves ischemia/reperfusion injury in rat lungs M Ishii, Y Suzuki, K Takeshita, N Miyao, H Kudo, R Hiraoka, K Nishio, ... The Journal of Immunology 172 (4), 2569-2577, 2004 | 102 | 2004 |
| Activity of nivolumab and utility of neutrophil-to-lymphocyte ratio as a predictive biomarker for advanced non–small-cell lung cancer: a prospective observational study T Fukui, Y Okuma, Y Nakahara, S Otani, S Igawa, M Katagiri, H Mitsufuji, ... Clinical lung cancer 20 (3), 208-214. e2, 2019 | 91 | 2019 |
| Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma J Hamamoto, K Soejima, S Yoda, K Naoki, S Nakayama, R Satomi, ... Molecular medicine reports 8 (2), 456-462, 2013 | 87 | 2013 |
| Overcoming EGFR bypass signal-induced acquired resistance to ALK tyrosine kinase inhibitors in ALK-translocated lung cancer M Miyawaki, H Yasuda, T Tani, J Hamamoto, D Arai, K Ishioka, K Ohgino, ... Molecular cancer research 15 (1), 106-114, 2017 | 73 | 2017 |
| Director’s Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma K Shedden, JM Taylor, SA Enkemann, MS Tsao, TJ Yeatman, WL Gerald, ... Gene expression-based survival prediction in lung adenocarcinoma: a multi …, 2008 | 73 | 2008 |